US President Donald Trump has announced deals that aim to lower the cost of popular weight-loss drugs, as pharmaceutical prices take centre stage in his administration's messaging around affordability.
Speaking alongside drug executives at the White House, Trump unveiled agreements with Eli Lilly and Novo Nordisk. Consumers are set to pay between $245 and $350 per month for obesity drugs including Wegovy and Zepbound.
Many GLP-1 drugs, used to treat diabetes and obesity, cost over $1,000 a month without insurance or discounts.
The deals will expand Eli Lilly and Novo Nordisk's access to Medicare and Medicaid, the government's public healthcare plans for elderly and low-income Americans.
Eli Lilly also said in a statement it would escape tariffs for three years as part of the agreement with the Trump administration.
